Eculizumab and aHUS: to stop or not
Robert A. Brodsky
Abstract
In this issue of Blood, Fakhouri et al(1) provide evidence in a prospective phase 4, multicentric, noncontrolled study that discontinuing eculizumab is safe in most patients with atypical hemolytic uremic syndrome (aHUS) once they achieve complete remission. Risk of relapse was <25% overall, but as high as 50% in patients with a rare variant in at least 1 complement gene.
Topics & Concepts
EculizumabMedicineAtypical hemolytic uremic syndromeImmunologyAntibodyComplement systemComplement system in diseasesTrypanosoma species research and implicationsPlatelet Disorders and Treatments